DE69839218D1 - Verfahren zur beseitigung von viren - Google Patents

Verfahren zur beseitigung von viren

Info

Publication number
DE69839218D1
DE69839218D1 DE69839218T DE69839218T DE69839218D1 DE 69839218 D1 DE69839218 D1 DE 69839218D1 DE 69839218 T DE69839218 T DE 69839218T DE 69839218 T DE69839218 T DE 69839218T DE 69839218 D1 DE69839218 D1 DE 69839218D1
Authority
DE
Germany
Prior art keywords
methods
immunoglobulin
excipient
removing viruses
nanofiltration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69839218T
Other languages
English (en)
Other versions
DE69839218T2 (de
Inventor
Holten Robert William Van
George E Oulundsen Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Clinical Diagnostics Inc
EMD Millipore Corp
Original Assignee
Ortho Clinical Diagnostics Inc
Millipore Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Clinical Diagnostics Inc, Millipore Corp filed Critical Ortho Clinical Diagnostics Inc
Application granted granted Critical
Publication of DE69839218D1 publication Critical patent/DE69839218D1/de
Publication of DE69839218T2 publication Critical patent/DE69839218T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0017—Filtration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/88—Manufacture, treatment, or detection of nanostructure with arrangement, process, or apparatus for testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Separation By Low-Temperature Treatments (AREA)
  • Glass Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Piles And Underground Anchors (AREA)
DE69839218T 1997-10-14 1998-10-14 Verfahren zur beseitigung von viren Expired - Lifetime DE69839218T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US950157 1992-09-29
US08/950,157 US6096872A (en) 1997-10-14 1997-10-14 Viral clearance process
PCT/US1998/021574 WO1999019343A1 (en) 1997-10-14 1998-10-14 Viral clearance process

Publications (2)

Publication Number Publication Date
DE69839218D1 true DE69839218D1 (de) 2008-04-17
DE69839218T2 DE69839218T2 (de) 2009-03-19

Family

ID=25490036

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69839218T Expired - Lifetime DE69839218T2 (de) 1997-10-14 1998-10-14 Verfahren zur beseitigung von viren

Country Status (12)

Country Link
US (1) US6096872A (de)
EP (1) EP1030862B1 (de)
JP (1) JP4255210B2 (de)
KR (1) KR100547077B1 (de)
CN (2) CN1163503C (de)
AT (1) ATE388162T1 (de)
AU (1) AU744845B2 (de)
CA (1) CA2306181C (de)
DE (1) DE69839218T2 (de)
ES (1) ES2302361T3 (de)
NO (1) NO326392B1 (de)
WO (1) WO1999019343A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2394797A1 (en) * 1999-12-20 2001-06-28 Tsuyoshi Takahashi Process for producing virus-free plasma protein composition by porous membrane treatment, virus-free plasma protein composition and method of removing viruses
DK1324776T4 (en) * 2000-10-12 2018-05-28 Genentech Inc CONCENTRATED PROTEIN FORMULATIONS WITH REDUCED VISCOSITY
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US6365395B1 (en) 2000-11-03 2002-04-02 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
AU784808B2 (en) * 2001-04-02 2006-06-29 Kedrion Melville Inc. Prion and viral clearance process
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
US6893639B2 (en) * 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
KR100451308B1 (ko) * 2001-12-28 2004-10-06 선바이오(주) 단백질 의약품 정제 방법에서의 바이러스 제거 방법
WO2003066669A2 (en) * 2002-02-04 2003-08-14 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
DE10211632A1 (de) * 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
AU2003241596B2 (en) * 2002-05-23 2010-01-21 Kedrion Melville Inc. Capture, concentration and quantitation of abnormal prior protein from biological fluids using depth filtration
US6773600B2 (en) * 2002-06-14 2004-08-10 Cantocor, Inc. Use of a clathrate modifier, to promote passage of proteins during nanofiltration
SI2261230T1 (sl) * 2002-09-11 2017-08-31 Chugai Seiyaku Kabushiki Kaisha Postopek čiščenja proteinov
US20040116676A1 (en) * 2002-09-30 2004-06-17 Hotta Joann Methods for removal of contaminants from blood product solutions
LT2335725T (lt) 2003-04-04 2017-01-25 Genentech, Inc. Didelės koncentracijos antikūno ir baltymo kompozicijos
WO2004103530A1 (en) * 2003-05-19 2004-12-02 Millipore Corporation Process for prefiltration of a protein solution
AU2005229674B2 (en) * 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment
US20060270015A1 (en) * 2005-05-26 2006-11-30 Dan Pawlak Thrombin purification
CA2655897C (en) * 2006-06-26 2015-09-29 Omrix Biopharmaceuticals Inc. Virus removal by nanofiltration
AU2007272494B2 (en) 2006-07-14 2011-07-28 Wisconsin Alumni Research Foundation Adsorptive membranes for trapping viruses
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
PT2271382E (pt) * 2008-04-15 2013-05-07 Grifols Therapeutics Inc Ultrafiltração em dois andares/diafiltração
KR20110128333A (ko) * 2009-03-06 2011-11-29 제넨테크, 인크. 항체 제제
JP5426019B2 (ja) * 2009-05-11 2014-02-26 イー・エム・デイー・ミリポア・コーポレイシヨン 混合工程のスケール方法
EP2652491B1 (de) 2010-12-15 2017-11-29 Baxalta GmbH Eluatsammlung mit leitfähigkeitsgradient
KR20120098202A (ko) * 2011-02-28 2012-09-05 (주)차바이오앤디오스텍 자하거 추출물 및 자하거 추출물 제조 방법
TR201810703T4 (tr) 2011-03-25 2018-08-27 Hoffmann La Roche Yeni protein saflaştırma yöntemleri.
EP2750784A1 (de) * 2011-09-01 2014-07-09 Chugai Seiyaku Kabushiki Kaisha Verfahren zur herstellung einer zusammensetzung mit hochkonzentrierten antikörpern durch ultrafiltration
CN102599332B (zh) * 2012-03-09 2014-07-30 上海杰隆生物制品股份有限公司 一种利用禽血生产低灰分禽血浆蛋白粉的方法
WO2014097289A1 (en) * 2012-12-20 2014-06-26 Omrix Biopharmaceuticals Ltd. Viral inactivated biological mixture
WO2015140751A1 (en) * 2014-03-21 2015-09-24 Boreal Invest Terminal nanofiltration of solubilized protein compositions for removal of immunogenic aggregates
EP4218991A1 (de) 2014-05-13 2023-08-02 Amgen Inc. Prozesssteuerungssysteme und verfahren zur verwendung mit filtern und filtrationsverfahren
CA2949696C (en) 2014-05-21 2023-08-08 Unchained Labs Systems and methods for exchange of buffer solutions
CN109563488B (zh) * 2016-08-09 2022-06-14 旭化成医疗株式会社 夹杂猪环状病毒的溶液的处理方法
EP3636657A1 (de) * 2018-10-08 2020-04-15 Ablynx N.V. Chromatographiefreies antikörperreinigungsverfahren
CN116297915B (zh) * 2023-02-10 2023-12-01 中国食品药品检定研究院 聚山梨酯类辅料的分析鉴定方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3449314A (en) * 1966-06-03 1969-06-10 Ortho Pharma Corp Preparation of anti-rh globulin from human plasma
US3916026A (en) * 1968-09-19 1975-10-28 Biotest Serum Institut Gmbh Method for the preparation of gamma-globulin suitable for intravenous use
US4021540A (en) * 1975-07-28 1977-05-03 Ortho Diagnostics Inc. Preparation of a hepatitis B immune globulin and use thereof as a prophylactic material
DE2624373C2 (de) * 1976-05-31 1983-02-03 Arnold Dr. 8782 Karlstadt Seufert Verfahren zur Herstellung von steril filtriertem Kryopräzipilat mit einer Anreicherung des Faktors VIII
US4590002A (en) * 1984-12-10 1986-05-20 Ortho Diagnostic Systems, Inc. Methods for preparation of highly purified, gamma globulins free of hepatitis-B-virus infectivity
DE3641115A1 (de) * 1986-12-02 1988-06-16 Lentia Gmbh Verfahren zur herstellung eines intravenoes anwendbaren und in fluessiger form stabilen immunglobulins
US5115101A (en) * 1988-06-08 1992-05-19 Miles Inc. Removal of protein A from antibody preparations
FR2639645B1 (fr) * 1988-11-25 1992-05-29 Elf Aquitaine Solutions liquides concentrees de polysaccharides
DE4137996A1 (de) * 1991-11-19 1993-05-27 Behringwerke Ag Verfahren zur herstellung eines virussicheren thrombinkonzentrates
SE9500724D0 (sv) * 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
FR2724182B1 (fr) * 1994-09-02 1996-12-13 Pasteur Institut Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations
US6498236B1 (en) * 1996-08-30 2002-12-24 Upfront Chromatography A/S Isolation of immunoglobulins

Also Published As

Publication number Publication date
AU1081799A (en) 1999-05-03
EP1030862B1 (de) 2008-03-05
JP4255210B2 (ja) 2009-04-15
CN1576281A (zh) 2005-02-09
DE69839218T2 (de) 2009-03-19
AU744845B2 (en) 2002-03-07
NO326392B1 (no) 2008-11-24
CA2306181C (en) 2010-09-21
JP2002500164A (ja) 2002-01-08
KR20010015753A (ko) 2001-02-26
NO20001949D0 (no) 2000-04-13
US6096872A (en) 2000-08-01
NO20001949L (no) 2000-06-14
CN1279688A (zh) 2001-01-10
CA2306181A1 (en) 1999-04-22
EP1030862A1 (de) 2000-08-30
ES2302361T3 (es) 2008-07-01
CN1163503C (zh) 2004-08-25
ATE388162T1 (de) 2008-03-15
WO1999019343A1 (en) 1999-04-22
CN1576281B (zh) 2012-08-08
KR100547077B1 (ko) 2006-02-01
EP1030862A4 (de) 2002-10-23

Similar Documents

Publication Publication Date Title
DE69839218D1 (de) Verfahren zur beseitigung von viren
ATE170630T1 (de) Proteine mit geänderten epitopen und verfahren zur deren herstellung
DE69632224D1 (de) Reduzierung von Gelation von Fettsäureacylierten Proteinen unter Nutzung von Zitratpuffer
CA2290485A1 (en) Method for the production of non-immunogenic proteins
ATE123780T1 (de) Verfahren zur verwendung und herstellung von peptiden.
NO177188C (no) Fremgangsmåte for separering av humane eller animalske plasmaproteiner
ATE200679T1 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
DE59003771D1 (de) Verfahren zur Herstellung von cyclischen Aminosäurederivaten sowie Zwischenprodukte.
DE69727595D1 (de) Verfahren zur herstellung eines extraktes des plättchenwachstumsfaktors für zubereitungen zur wundheilung
DE3768833D1 (de) Verfahren zur herstellung von hcmv-glykoproteinen, antikoerper dagegen und hcmv-vakzine und dazu zu verwendende rekombinante vektoren.
ATE154200T1 (de) Verfahren zur gewinnung von alpha-lactalbumin und beta-lactoglobulin aus einem molkeproteinprodukt
DE3773963D1 (de) Verfahren zur herstellung von reifem, menschlichem serum-albumin.
DK322188A (da) Fremgangsmaade til fremstilling af protein
ATE432948T1 (de) Verfahren zur beseitigung von viren und prionen aus immunglobulinzusammensetzungen
DE69506338D1 (de) Verfahren und Gerät zur Herstellung von supraleitenden Komponenten via Laserablation, gefolgt durch Laserbearbeitung
DE59209512D1 (de) Hcv peptidantigene und verfahren zur bestimmung von hcv
BR9709569A (pt) Processo para ativação de proteína desnaturada
ATE245192T1 (de) Verfahren zur herstellung von gereinigten papillomavirus proteinen
ATA185883A (de) Verfahren zur herstellung einer faktor viii (ahf) -haeltigen praeparation
DE69434221D1 (de) Bindungs domänen von plasmodium vivax und plasmodium falciparum erythrozyten-bindenden proteinen
ES534008A0 (es) Procedimiento de separacion de las principales proteinas de la sangre hemolizada
ATE212360T1 (de) Polyethylenglycol-hirudin-konjugate, deren verfahren zur herstellung und verwendung für die heilung von thrombosen
ATE140485T1 (de) Co-hydrolytsches verfahren zur herstellung von extrakten aus hefe und nicht-hefe proteinen
ATE118982T1 (de) Verfahren zur herstellung von transparenten milchmolkeproteinen und milchmolkeproteinprodukte.
ATE250132T1 (de) Verfahren zur extraktion von periplasmatischen proteinen aus prokaryotischen mikroorganismen in der anwesenheit von arginin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1030862

Country of ref document: EP

Representative=s name: MUELLER-BORE & PARTNER PATENTANWAELTE, EUROPEA, DE